{"symbol":"BMY","fiscalQuarter":"Q4-2017","reportDate":"2018-02-05","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2017","postBrief":{"headline":"Bristol Myers Squibb Misses on EPS, Stock Down 3.97%","keyNumbers":[{"metric":"EPS","actual":"$0.68","expected":"N/A","surprise":"-0.41%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management highlighted ongoing challenges in the market.","They emphasized the need for strategic adjustments moving forward."],"summary":"Management expressed concerns about current market conditions impacting performance. They are focused on adapting strategies to navigate these challenges."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report indicates a slight miss on EPS, which contributed to a 3.97% decline in stock price. Investors may be reacting to management's cautious tone regarding market challenges. The lack of guidance could lead to uncertainty about future performance.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2017 earnings: EPS missed. Stock down 3.97%. Full breakdown."}}